Your browser doesn't support javascript.
loading
Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer.
Rautela, Jai; Baschuk, Nikola; Slaney, Clare Y; Jayatilleke, Krishnath M; Xiao, Kun; Bidwell, Bradley N; Lucas, Erin C; Hawkins, Edwin D; Lock, Peter; Wong, Christina S; Chen, Weisan; Anderson, Robin L; Hertzog, Paul J; Andrews, Daniel M; Möller, Andreas; Parker, Belinda S.
Afiliação
  • Rautela J; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia. Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
  • Baschuk N; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.
  • Slaney CY; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia. Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
  • Jayatilleke KM; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.
  • Xiao K; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.
  • Bidwell BN; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Lucas EC; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Hawkins ED; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Lock P; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.
  • Wong CS; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
  • Chen W; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.
  • Anderson RL; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia. Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.
  • Hertzog PJ; Centre for Innate Immunity and Infectious Diseases, Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia.
  • Andrews DM; Department of Immunology, Monash University Central Clinical School, Alfred Medical Research and Education Precinct (AMREP), Melbourne, Victoria, Australia.
  • Möller A; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
  • Parker BS; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia. Belinda.Parker@latrobe.edu.au.
Cancer Immunol Res ; 3(11): 1207-17, 2015 Nov.
Article em En | MEDLINE | ID: mdl-26198985
ABSTRACT
Metastatic progression is the major cause of breast cancer-related mortality. By examining multiple syngeneic preclinical breast cancer models in mice lacking a functional type-I interferon receptor (Ifnar1(-/-) mice), we show that host-derived type-I interferon (IFN) signaling is a critical determinant of metastatic spread that is independent of primary tumor growth. In particular, we show that bone metastasis can be accelerated in Balb/c Ifnar1(-/-) mice bearing either 4T1 or 66cl4 orthotopic tumors and, for the first time, present data showing the development of bone metastasis in the C57Bl/6 spontaneous MMTV-PyMT-driven model of tumorigenesis. Further exploration of these results revealed that endogenous type-I IFN signaling to the host hematopoietic system is a key determinant of metastasis-free survival and critical to the responsiveness of the circulating natural killer (NK)-cell population. We find that in vivo-stimulated NK cells derived from wild-type, but not Ifnar1(-/-), mice can eliminate the 4T1 and 66cl4 breast tumor lines with varying kinetics in vitro. Together, this study indicates that the dysregulated immunity resulting from a loss of host type-I IFN signaling is sufficient to drive metastasis, and provides a rationale for targeting the endogenous type-I IFN pathway as an antimetastatic strategy.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Células Matadoras Naturais / Interferon Tipo I / Neoplasias Mamárias Experimentais Limite: Animals Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Células Matadoras Naturais / Interferon Tipo I / Neoplasias Mamárias Experimentais Limite: Animals Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Austrália